Elan Corporation PLC
featured
Some of the names on the move ahead of the open.
» Read More
More
-
NEW YORK-- Royalty Pharma disclosed Friday that a negligible number of Elan Corp. PLC shareholders have voted their shares in favor of its offer to buy the company. The New York company offered to buy Elan in February for $11 per share and later raised the offer to $11.25 per share.
-
NEW YORK-- Alkermes PLC said Thursday that it was profitable in its fiscal fourth quarter as it received bigger royalty payments and more revenue for drug manufacturing. Alkermes said it earned $3 million, or 2 cents per share, over the three months ended March 31.
-
DUBLIN, May 13- Irish drugmaker Elan Corporation has agreed a $1 billion royalties deal that could soothe concerns about its potentially risky acquisition strategy and fend off a takeover bid from Royalty Pharma.
-
Elan stepped up its bid to keep its independence on Monday by agreeing a $1 billion deal to buy 21 percent of the royalties that U.S. company Theravance receives from GlaxoSmithKline.
-
*SAC Capital employee loses bid for new judge. NEW YORK, May 3- A federal judge has set Nov. 18 for the start of the criminal trial of Michael Steinberg, the most senior employee of Steven A. Cohen's hedge fund SAC Capital Advisors to be indicted for insider trading.
-
*Royalty submits offer document for Elan Corp. DUBLIN, May 2- Royalty Pharma submitted its $11.25 per share bid for Elan to the Irish drugmaker's shareholders on Thursday, standing by its reduced price in the face of the target's insistence it is worth more.
-
May 2- Elan Corporation PLC:. *Royalty pharma- submits formal cash offer for Elan Corporation; offer price. reflects $1 billion Dutch auction strikeprice of $11.25 per Elan share.
-
DUBLIN, May 2- Elan considered buying U.S. investment firm Royalty Pharma last year, six months before Royalty made its approach for the Irish drugmaker, the offer document for the bid showed on Thursday. Royalty submitted its $5.7 billion bid on Thursday, standing by a reduced price in the face of Elan's insistence it is worth more.
-
April 30- Gerson Lehrman Group, the country's largest expert network firm, has hired a U.S. Securities and Exchange Commission enforcement attorney to serve as its chief compliance counsel, the company confirmed on Tuesday.
-
*Royalty had urged shareholders to tender at $11.75 or $12. DUBLIN/ NEW YORK, April 18- U.S. healthcare firm Johnson& Johnson cut its stake in Elan Corp on Thursday in a move that clouds prospects for a $7.3 billion takeover bid for the Irish drugmaker.
-
In the aftermath of the Boston Marathon explosions, counterterrorism officials have found what they believe to be five additional, undetonated explosive devices around the Boston area.
-
In the aftermath of the Boston Marathon explosions, counterterrorism officials have found what they believe to be five additional, undetonated explosive devices around the Boston area.
-
*Citigroup climbing back up league tables. NEW YORK, April 15- In the summer of 2010, senior executives at Citigroup Inc told the board of directors the bank needed to hire more dealmakers to have any chance of snagging underwriting assignments and rich takeover advisory fees.
-
*Thermo Fisher in $13.6 bln Life Tech takeover. *Dish Network bids for Sprint Nextel. Dish Network Corp, the No. 2 U.S. satellite television provider, made a $25.5 billion bid for Sprint Nextel Corp, challenging the proposed acquisition of Sprint by Japan's SoftBank Corp, while Thermo Fisher Scientific Inc struck a $13.6 billion deal to buy Life Technologies Corp..
-
European shares closed lower on Monday, after news of an unexpected slowdown in China sparked a commodities sell-off.
-
April 15- U.S. investment firm Royalty Pharma sweetened its bid for Irish drugmaker Elan Corp, on Monday, offering what it called "a firm, all cash offer" worth as much as $12 per share, depending on the outcome of a Dutch auction. Royalty Pharma said the offer will be financed through a combination of existing resources and new credit facilities.